FSTL3 and pulmonary arterial hypertension: After excluding subjects with ILD and patients treated for PAH, FSTL3 and MDK remained elevated (p < 0.05) in SSc-PAH patients compared to lcSSc-no PAH (Additional file 9: Figure S5).